Lumosa Therapeutics Co. Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; L… Read more
Lumosa Therapeutics Co. Ltd. (6535) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.028x
Based on the latest financial reports, Lumosa Therapeutics Co. Ltd. (6535) has a cash flow conversion efficiency ratio of -0.028x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-42.42 Million) by net assets (NT$1.52 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lumosa Therapeutics Co. Ltd. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Lumosa Therapeutics Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lumosa Therapeutics Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lumosa Therapeutics Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SSAW Hotels & Resorts Group Co.Ltd.
SHE:301073
|
N/A |
|
Doman Building Materials Group Ltd
PINK:CWXZF
|
0.115x |
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
0.052x |
|
KOMORI CORP.
F:KOI
|
N/A |
|
Vontron Technology Co Ltd
SHE:000920
|
0.022x |
|
Xinyaqiang Silicon Chemistry Co Ltd
SHG:603155
|
0.015x |
|
Elec-Tech International Co Ltd
SHE:002005
|
-0.147x |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
0.123x |
Annual Cash Flow Conversion Efficiency for Lumosa Therapeutics Co. Ltd. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Lumosa Therapeutics Co. Ltd. from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.52 Billion | NT$-360.50 Million | -0.237x | -54.35% |
| 2024-12-31 | NT$1.93 Billion | NT$-296.33 Million | -0.154x | +33.08% |
| 2023-12-31 | NT$1.43 Billion | NT$-328.21 Million | -0.230x | -27.70% |
| 2022-12-31 | NT$1.67 Billion | NT$-300.46 Million | -0.180x | +15.78% |
| 2021-12-31 | NT$2.12 Billion | NT$-452.60 Million | -0.214x | -161.88% |
| 2020-12-31 | NT$1.58 Billion | NT$-129.11 Million | -0.082x | +77.52% |
| 2019-12-31 | NT$1.05 Billion | NT$-379.52 Million | -0.363x | -- |